An interventional study of Epygon™ Transcatheter Mitral Valve System in Mitral Valve Regurgitation, sponsored by Epygon. Recruiting at 10 sites in 4 countries. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2023-08-07.
Sponsored by Epygon · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Mitral Valve Insufficiency with a site in Spain — 11 open to participants now, 15 under way, none of them phase 3. Mitral Valve Insufficiency · Spain.
Among the 20 studies in Mitral Valve Insufficiency with a site in Spain, this one is the 8th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2021, is one of 11 with no phase, reaches primary completion later than 2 of the 14 other live ones, and was the 10th registered.
471 studies on the registry are indexed under Mitral Valve Insufficiency; 165 are open to participants now.
Browse Mitral Valve Insufficiency studies →11 of the 20 studies in Mitral Valve Insufficiency with a site in Spain are open now. Recruiting first, the newest first:
Germans Trias i Pujol Hospital · Sites in Spain
Ages 18–95
Fundación para la Investigación Biosanitaria del Principado de Asturias · Sites in Spain, Israel, Italy and 1 more country
Ages 18–99
Shanghai Shenqi Medical Technology Co., Ltd · Sites in Spain
Ages 18+
4C Medical Technologies, Inc. · Sites in Spain, United States, Canada and 4 more countries
Ages 18+
Medtronic Cardiovascular · Sites in Spain, Denmark, France and 5 more countries
Ages 18+
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 121 Mitral Valve Insufficiency studies recruiting now, 100 (83%) set no upper age limit and 6 (5%) stop at 75 or younger; 12 take children under 18; 1 takes healthy volunteers.
This study: 60 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 4 started in 2021.
This study's planned enrollment of 40 is below the median of 69 across 280 interventional studies indexed under Mitral Valve Insufficiency.
Median enrollment 204 across the 12 interventional studies, 775 across the 8 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 20 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Epygon as lead sponsor.
Epygon has 1 study filed under Mitral Valve Insufficiency — fewer than ten, so there is no comparison to draw.
4 of the studies in Mitral Valve Insufficiency with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03142152Cardiac Dimensions, Inc.The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With FMR | 2026-12-31 |
| NCT04898335LMU KlinikumTendyne European Experience Registry | 2026-12-31 |
| NCT06823700Shanghai Shenqi Medical Technology Co., LtdSafety and Effectiveness Study of SQ-Kyrin System for Functional Mitral Regurgitation in EU | 2026-12-31 |
| NCT06282042Fundación para la Investigación Biosanitaria del Principado de AsturiasEarly Transcatheter Mitral Valve Repair After Myocardial Infarction | 2027-06-16 |
Add all 4 to your calendar (.ics) → With an account.
Among the 20 studies in Mitral Valve Insufficiency with a site in Spain, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device.
The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.
The purpose of this trial is to assess the safety and feasibility of the Epygon™ Transcatheter mitral valve and the transapical delivery system, in adult patients with severe, symptomatic mitral regurgitation.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients unable to read and write.
Patients with a systolic/diastolic mitral valve area assessed as not compatible with the sizing policy matrix defined by the Sponsor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Implantation of Epygon mitral valve prosthesis
Device: Epygon™ Transcatheter Mitral Valve System
The EPYGON VALVE is an innovative mitral valve, intended for valve replacement of a native mitral valve through a minimally invasive implant procedure by means of a dedicated implant device. The EPYGON VALVE is a bio prosthesis, composed by a functional assembly of bovine pericardium on a NiTinol stent.
Device Safety
defined as the absence of major device or procedure related serious adverse events evaluated on the following clinical events: 1. death 2. major cardiac structural complications (as per MVARC definitions) 3. life-threatening bleeding (MVARC scale) 4. any prosthesis-related dysfunction, migration, thrombosis, or other complication, that require surgery or repeated intervention. 5. myocardial infarction or coronary ischemia requiring PCI or CABG 6. severe hypotension, heart failure or respiratory failure requiring intravenous vasopressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for ≥ 48H 7. major vascular complications 8. stroke 9. stage 2 or 3 acute kidney injury (includes new dialysis)
Time frame: [Timeframe: at 30 days]
Device Success
1. Technical Success (as per MVARC definition) defined as alive patient at exit from procedure room, with all of the following: 1. Successful access, delivery and retrieval of the Epygon delivery system 2. Successful deployment and positioning of the Epygon Transcatheter mitral valve 3. Freedom from additional emergency surgery or re-intervention related to the device or access procedure. 2. Continued intended safety and performance of the device, including: 1. No evidence of structural or functional failure (as per MVARC definition) 2. No specific device-related technical failure issues and complications (as per MVARC definition) 3. Reduction of mitral regurgitation (MR) to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR) without significant mitral stenosis (post-procedure EOA ≥ 1.5 cm2 with a transmitral gradient \< 5mmHg) and with no greater than mild (1+) paravalvular MR (and without associated hemolysis)
Time frame: [Timeframe: at 30 days]
Device Safety
defined as absence of major device or procedure related serious adverse events evaluated on the following clinical events: 1. death 2. major cardiac structural complications 3. life-threatening bleeding (MVARC scale) 4. any prosthesis-related dysfunction, migration, thrombosis, or other complication, that require surgery or repeated intervention. 5. myocardial infarction or coronary ischemia requiring PCI or CABG 6. severe hypotension, heart failure or respiratory failure requiring intravenous vasopressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for ≥ 48H 7. major access complications 8. stroke 9. stage 2 or 3 acute kidney injury (includes new dialysis)
Time frame: [Time frame: 3, 6, 12 months and yearly up to 5 years from implantation]
Patient success (as per MVARC definition)
All of the following must be present: 1. Device success (either optimal or acceptable) 2. Patient returned to the pre-procedural setting 3. No rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, heart failure) 4. Improvement from baseline in symptoms (e.g., NYHA improvement by ≥ 1 functional class) 5. Improvement from baseline in functional status (e.g., 6-min walk test improvement by ≥ 50 m) 6. Improvement from baseline in quality-of-life (e.g., Kansas City Cardiomyopathy Questionnaire improvement by ≥ 10)
Time frame: [Time frame: 12 months from implantation]
Evaluation of clinical status on the basis of the NYHA functional classification
Time frame: [Time frame Preoperative, 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Six-minute walk test
Time frame: [Time frame: Preoperative, 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Quality of Life score (Kansas City Cardiomyopathy Questionnaire)
The Kansas City Cardiomyopathy Questionnaire is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. Scores are transformed to a range of 0-100, in which higher scores reflect better health status.
Time frame: [Time frame: Preoperative, 3, 6, 12 months and yearly up to 5 years from implantation]
Hemodynamic performance assessed by echocardiography
1. Prosthetic mean atrio-ventricular ΔP \< 5 mm Hg 2. Prosthetic Effective Orifice Area (EOA) ≥ 1.5 cm2 3. Mitral valve regurgitation reduction (vs. preoperative) of at least 1 grade and not more than moderate (2+) 4. Prosthetic paravalvular valve leakage (PVL) not more than mild (1+) without hemolysis
Time frame: [Time frame: Preoperative on native mitral valve, Postoperative, 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Technical Success (as per MVARC definition)
defined as alive patient at exit from procedure room, with all of the following: 1. Successful access, delivery and retrieval of the Epygon delivery system 2. Successful deployment and positioning of the Epygon Transcatheter mitral valve 3. Freedom from additional emergency surgery or re-intervention related to the device or access procedure.
Time frame: [Time Frame: immediately after procedure]
Device Success
1. Technical Success (as per MVARC definition) defined as alive patient at exit from procedure room, with all of the following: 1. Successful access, delivery and retrieval of the Epygon delivery system 2. Successful deployment and positioning of the Epygon bioprosthesis 3. Freedom from additional emergency surgery or re-intervention related to the device or access procedure. 2. Continued intended safety and performance of the device, including: 1. No evidence of structural or functional failure (as per MVARC definition) 2. No specific device-related technical failure issues and complications (as per MVARC definition) 3. Reduction of mitral regurgitation (MR) to either optimal (0+ to trace) or acceptable (reduced by at least 1 grade from baseline with no more than 2+ MR) without significant mitral stenosis (post-procedure EOA ≥ 1.5 cm2 with a transmitral gradient \< 5mmHg) and with no greater than mild (1+) paravalvular MR (and without associated hemolysis)
Time frame: [Time frame: 3, 6, 12 months and yearly up to 5 years from implantation]
Procedural Success
All of the following must be present: 1. Device success (either optimal or acceptable), And 2. Absence of major device or procedure related serious adverse events, including: 1. death 2. major cardiac structural complications (as per MVARC definitions) 3. life-threatening bleeding (MVARC scale) 4. any prosthesis-related dysfunction, migration, thrombosis, or other complication, that require surgery or repeated intervention. 5. myocardial infarction or coronary ischemia requiring PCI or CABG 6. severe hypotension, heart failure or respiratory failure requiring intravenous vasopressors or invasive or mechanical heart failure treatments such as ultrafiltration or hemodynamic assist devices, including intra-aortic balloon pumps or left ventricular or biventricular assist devices, or prolonged intubation for ≥ 48H 7. major vascular complications 8. stroke 9. stage 2 or 3 acute kidney injury (includes new dialysis).
Time frame: [Time frame: 30 days]
Incidence of adverse events
Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Incidence of serious adverse events
Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Incidence of adverse events related to device
Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Incidence of adverse events related to procedure
Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Absence of all-cause mortality
Time frame: [Time frame: 30 days, 3, 6, 12 months and yearly up to 5 years from implantation]
Started Feb 2021 (actual). Primary completion is estimated for Oct 2024, 44 months after the start.
Of 91 industry-sponsored interventional studies with no phase under Mitral Valve Insufficiency, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 144. This study's planned 44 months is below that.
Counting every sponsor, half of 144 studies reached it within 56 months; a quarter within 25 and three quarters within 108.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.